Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 20/20 | 1.00 |
| ▸ | AR | P10275 | 3/20 | 0.60 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.60 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185522 | 0.99 | PGR (0.98) | PGRARNR3C1NR3C2 | |
| SCHEMBL13579113 | 0.87 | PGR (0.77) | PGRARNR3C1NR3C2 | |
| SCHEMBL5524424 | 0.86 | PGR (0.76) | PGRARNR3C1NR3C2 | |
| Tanaproget SCHEMBL62188 | 0.86 | PGR (1.00) | PGRNR3C1 | |
| SCHEMBL7686696 | 0.85 | PGR (0.74) | PGRARNR3C1NR3C2 | |
| SCHEMBL1224081 | 0.85 | PGR (1.00) | PGRARNR3C1NR3C2 | |
| SCHEMBL5518269 | 0.85 | PGR (0.74) | PGRARNR3C1NR3C2 | |
| SCHEMBL5515556 | 0.84 | PGR (0.72) | PGRARNR3C1NR3C2 | |
| SCHEMBL5514404 | 0.84 | PGR (0.72) | PGRARNR3C1NR3C2 | |
| SCHEMBL5515576 | 0.84 | PGR (0.72) | PGRARNR3C1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476262-B2 | Cyanopyrroles | WYETH LLC (US) | 2013-07-02 | — | — | US | claimed |
| US-8129523-B2 | Coupling process for generating reactive boron-containing derivatives of N-substituted pyrrole-2-carbonitriles to produce biaryls | WYETH LLC (US) | 2012-03-06 | — | — | US | claimed |
| EP-1173433-B1 | CYANOPYRROLES AS PROGESTERONE RECEPTOR AGONISTS | WYETH CORP (US) | 2005-12-28 | — | — | EP | claimed |
| WO-2014159377-A1 | COMPOSITIONS CONTAINING TANAPROGET AND NATURAL ESTROGENS | TEVA WOMEN'S HEALTH, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-8796266-B2 | Cyclothiocarbamate derivatives as progesterone receptor modulators | WYETH LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140194398-A1 | Tanaproget Compositions Containing Ethinyl Estradiol | WYETH LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-8664208-B2 | Tanaproget compositions containing ethinyl estradiol | WYETH LLC (US) | 2014-03-04 | — | — | US | disclosed |
| US-8609712-B2 | Purification of progesterone receptor modulators | WYETH LLC (US) | 2013-12-17 | — | — | US | disclosed |
| US-20130261112-A1 | Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators | WYETH LLC | 2013-10-03 | — | — | US | disclosed |
| US-8476262-B2 | Cyanopyrroles | WYETH LLC (US) | 2013-07-02 | — | — | US | disclosed |
| US-8466146-B2 | Cyclothiocarbamate derivatives as progesterone receptor modulators | WYETH LLC (US) | 2013-06-18 | — | — | US | disclosed |
| WO-2005104711-A2 | PURIFICATION OF PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050250766-A1 | Purification of progesterone receptor modulators | WYETH (US) | 2005-11-10 | — | — | US | disclosed |
| US-20050227971-A1 | Thioamide derivatives as progesterone receptor modulators | WYETH (US) | 2005-10-13 | — | — | US | disclosed |
| US-20030158182-A1 | A progesterone receptor antagonist for providing progestational therapy, treating cancer of breast, uterine, ovarian, endometrial, or prostate, providing contraceptives, hormone replacement therapy | WYETH | 2003-08-21 | — | — | US | disclosed |
| US-20030092711-A1 | Contraceptives; hormone replacement therapy | WYETH LLC | 2003-05-15 | — | — | US | disclosed |
| US-6562857-B2 | Progesterone receptor antagonist; inhibiting breast, uterine, ovarian, endometrial, or prostate cancer | WYETH | 2003-05-13 | — | — | US | disclosed |
| US-6436929-B1 | 3,1-BENZOXAZINE-2-THIONES; CONTRACEPTION AND THE TREATMENT OF PROGESTERONE-RELATED MALADIES | WYETH | 2002-08-20 | — | — | US | disclosed |
| US-6407101-B1 | PROGESTERONE RECEPTOR ANTAGONISTS; CONTRACEPTIVES, HORMONE REPLACEMENT THERAPY; BREAST AND PROSTATE CANCER TREATMENT; MENOPAUSE | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-18 | — | — | US | disclosed |
| US-20020068735-A1 | Cyanopyrroles | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227971-A1 | Thioamide derivatives as progesterone receptor modulators | PGR, PGRMC2, PGRMC1 | PGR 1/4885AR 69/4885NR3C1 33/4885 |
| US-20020068735-A1 | Cyanopyrroles | PGR, NR3C2, GNRHR | PGR 1/4885AR 28/4885NR3C1 19/4885 |
| US-20030092711-A1 | Contraceptives; hormone replacement therapy | PGR, GNRHR, GHRHR | PGR 1/4885AR 31/4885NR3C1 14/4885 |
| US-20130261112-A1 | Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators | PGR, PGRMC2, PGRMC1 | PGR 1/4885AR 97/4885NR3C1 17/4885 |
| US-20030158182-A1 | A progesterone receptor antagonist for providing progestational therapy, treating cancer of breast, uterine, ovarian, endometrial, or prostate, providing contraceptives, hormone replacement therapy | PGR, GNRHR, AR | PGR 1/4885AR 3/4885NR3C1 27/4885 |
| US-20050250766-A1 | Purification of progesterone receptor modulators | PGR, PGRMC1, PGRMC2 | PGR 1/4885AR 22/4885NR3C1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.